Cerebral Venous Sinus Thrombosis Medical Services in China

Cerebral Venous Sinus Thrombosis (CVST) is a rare but potentially life-threatening cerebrovascular disorder characterized by the formation of a thrombus within the dural venous sinuses or cortical veins of the brain. Unlike ischemic stroke caused by arterial occlusion, CVST impairs venous outflow, leading to increased intracranial pressure, venous congestion, cerebral edema, and, in severe cases, hemorrhagic infarction or brain herniation. Pathogenesis involves a complex interplay of Virchow’s triad—venous stasis, endothelial injury, and hypercoagulability. Common underlying mechanisms include inherited or acquired thrombophilias (e.g., factor V Leiden, protein C/S deficiency, antiphospholipid syndrome), hormonal influences (especially estrogen-containing contraceptives or pregnancy/postpartum states), infections (e.g., mastoiditis, sinusitis, meningitis), malignancy, autoimmune disorders (e.g., systemic lupus erythematosus), dehydration, and inflammatory conditions such as Behçet’s disease. CVST accounts for less than 1% of all strokes but disproportionately affects younger adults (median age 37–45 years) and women of childbearing age. Its annual incidence is estimated at 3–5 cases per million population globally, though underdiagnosis remains common due to nonspecific presentation. Key risk factors include oral contraceptive use (up to 8-fold increased risk), recent pregnancy or puerperium (10–20× higher risk), active cancer, chronic inflammatory diseases, nephrotic syndrome, and central nervous system infection or trauma. Clinical manifestations vary widely—from isolated headache (present in >90% of cases) to focal neurological deficits, seizures, altered consciousness, visual disturbances, or coma. Delayed diagnosis significantly worsens prognosis: mortality ranges from 5% to 15% in modern series, with up to one-third of survivors experiencing persistent neurological sequelae—including chronic headache, cognitive impairment, epilepsy, or motor deficits. Quality of life impact is substantial: patients often face prolonged recovery, vocational limitations, anxiety about recurrence, and challenges accessing specialized neuro-hematologic care. Long-term anticoagulation management requires careful monitoring to balance thrombotic and hemorrhagic risks, adding psychological and socioeconomic burdens. Early recognition, prompt neuroimaging (MRI/MRV or CT/CTV), and multidisciplinary management involving hematology, neurology, and neuroradiology are critical to optimizing outcomes.

Cerebral Venous Sinus Thrombosis (CVST) is a rare but potentially life-threatening cerebrovascular disorder characterized by thrombus formation within the dural venous sinuses or cortical veins. Unlike arterial stroke, CVST disrupts venous outflow, leading to increased intracranial pressure, venous congestion, hemorrhagic infarction, and, in severe cases, brain herniation. Prompt diagnosis—typically via MRI with MR venography or CT venography—and early intervention are critical to prevent mortality (historically 5–10%, now <5% with modern management) and long-term neurological disability. Management is multidisciplinary, involving hematologists, neurologists, neuroradiologists, and neurointensivists. Treatment strategies are stratified by clinical severity, etiology, imaging findings, and comorbidities.

Conservative treatment forms the cornerstone of initial management for most patients without signs of rapid neurological deterioration or mass effect. It includes strict neurological monitoring in an intensive care or step-down unit, with serial assessments of consciousness level (GCS), pupillary response, and focal deficits. Intracranial pressure (ICP) management is essential: head-of-bed elevation to 30°, avoidance of jugular venous compression (e.g., tight cervical collars, excessive neck flexion), and correction of hypoxia, hypercapnia, and fever. Seizure prophylaxis is not routinely recommended unless there is cortical involvement, hemorrhage, or prior seizure; however, antiepileptic drugs (e.g., levetiracetam) are initiated promptly if seizures occur. Fluid balance must be carefully maintained—hypotonic fluids are avoided to prevent worsening cerebral edema; isotonic saline (0.9% NaCl) is preferred. In patients with elevated ICP refractory to conservative measures, therapeutic lumbar puncture may be considered cautiously—if imaging excludes transverse sinus occlusion with significant pressure gradient or impending herniation—to reduce CSF pressure and alleviate headache and papilledema. However, this is contraindicated in the presence of large venous infarcts or midline shift due to risk of transtentorial herniation.

Anticoagulation remains the primary pharmacologic intervention for nearly all CVST patients, regardless of hemorrhagic conversion on imaging. Evidence from randomized trials (e.g., TO-ACT) and meta-analyses confirms that anticoagulation significantly reduces mortality and dependency without increasing symptomatic intracranial hemorrhage risk. Initial parenteral anticoagulation—preferably low-molecular-weight heparin (LMWH) such as enoxaparin (1 mg/kg subcutaneously twice daily)—is administered unless absolute contraindications exist (e.g., active major bleeding, intracranial hemorrhage with expanding mass effect, or severe thrombocytopenia <50 × 10⁹/L). LMWH is favored over unfractionated heparin due to more predictable pharmacokinetics, lower risk of heparin-induced thrombocytopenia (HIT), and no requirement for frequent aPTT monitoring. After clinical stabilization (typically within 5–10 days), transition to oral anticoagulation is undertaken. Vitamin K antagonists (e.g., warfarin) with target INR 2.0–3.0 remain standard for patients with provoked CVST (e.g., postpartum, infection, malignancy) or those requiring long-term therapy. Direct oral anticoagulants (DOACs)—including apixaban, rivaroxaban, and dabigatran—are increasingly supported by emerging evidence (e.g., the RE-SPECT CVST trial) for safety and non-inferiority in unprovoked or idiopathic CVST, though caution is advised in patients with severe renal impairment, active malignancy, or extensive cortical vein involvement. Duration of anticoagulation depends on etiology: 3 months for transient risk factors (e.g., pregnancy, oral contraceptive use); 6–12 months for persistent prothrombotic states (e.g., antiphospholipid syndrome, factor V Leiden heterozygosity); and indefinite therapy for recurrent CVST or high-risk thrombophilias (e.g., homozygous mutations, antiphospholipid syndrome with arterial events). Adjunctive therapies include corticosteroids only in specific contexts—e.g., cerebral edema secondary to inflammatory conditions like sarcoidosis or Behçet disease—not routine CVST. Thrombolytics are reserved for fulminant cases with rapid neurological decline despite full-dose anticoagulation and are typically delivered via endovascular route.

Surgical intervention is rarely indicated but lifesaving in select scenarios. Decompressive craniectomy is performed for malignant cerebral edema with impending herniation unresponsive to medical therapy—particularly in patients with large venous infarcts and midline shift >5 mm. Studies demonstrate improved survival and functional outcomes when performed early (within 48 hours of deterioration). Endovascular mechanical thrombectomy and/or local intra-sinus thrombolysis (e.g., urokinase or alteplase infusion) may be considered in patients with progressive neurological deficits despite anticoagulation, especially those with dominant sinus occlusion (e.g., superior sagittal or transverse sinus) and preserved penumbra on perfusion imaging. These procedures require specialized neurointerventional centers and carry risks including vessel perforation, distal embolization, and hemorrhage. Surgical venous sinus stenting is investigational and currently limited to highly selected cases of chronic CVST with residual stenosis and refractory intracranial hypertension—its role remains undefined outside expert centers.

China offers distinct advantages in CVST management, particularly through its integrated national healthcare infrastructure and rapidly advancing neurovascular capabilities. Over 200 certified Comprehensive Stroke Centers—including top-tier institutions like Beijing Tiantan Hospital, Huashan Hospital (Shanghai), and West China Hospital (Chengdu)—provide standardized, protocol-driven care aligned with Chinese Stroke Prevention and Treatment Guidelines and international consensus (e.g., ESO, AHA/ASA). China’s centralized thrombophilia screening programs enable rapid identification of inherited (e.g., protein C/S deficiency, MTHFR polymorphisms) and acquired (e.g., antiphospholipid antibodies, JAK2 V617F in myeloproliferative neoplasms) etiologies. The widespread adoption of AI-assisted MRI/MRV interpretation improves diagnostic accuracy and turnaround time. Moreover, China’s robust generic pharmaceutical industry ensures reliable access to high-quality LMWH, warfarin, and increasingly DOACs at significantly lower cost than in many Western countries—enhancing treatment adherence and equity. Clinical trial participation (e.g., CHANCE-3, ongoing CVST registries) further strengthens evidence generation tailored to East Asian populations, who exhibit differing prevalence of risk factors (e.g., higher rates of Behçet disease, lower prevalence of factor V Leiden).

Recovery requires structured, individualized rehabilitation and long-term follow-up. Patients should undergo neuropsychological assessment to detect subtle cognitive deficits (e.g., executive dysfunction, memory impairment), which affect up to 30% of survivors. Physical, occupational, and speech therapy are initiated early—even during acute hospitalization—for those with motor, coordination, or language deficits. Anticoagulation duration and monitoring must be coordinated between hematologists and primary care providers, with regular CBC, liver/kidney function, and INR checks (if on warfarin). Lifestyle counseling emphasizes avoidance of estrogen-containing contraceptives, smoking cessation, hydration, and management of modifiable risks (hypertension, obesity, immobility). Psychosocial support is vital: depression and anxiety are prevalent post-CVST and correlate with poorer functional outcomes. Follow-up neuroimaging (MRV) is recommended at 3–6 months to assess recanalization, though clinical status—not imaging alone—guides therapeutic decisions. Most patients achieve good functional recovery (mRS ≤2) within 6–12 months; however, persistent headache, fatigue, and epilepsy may require prolonged symptomatic management. Long-term hematologic evaluation is mandatory to exclude occult malignancy or myeloproliferative disorders—especially in patients aged >50 years or with unexplained recurrent thrombosis.